Skip to main content

Table 1 Characteristics of the 5 hematopoietic stem cell transplantation (HSCT) patients presenting WUPyV or KIPyV

From: The polyomaviruses WUPyV and KIPyV: a retrospective quantitative analysis in patients undergoing hematopoietic stem cell transplantation

Virus Patient Transplant type GvHD Antiviral therapy Co-infecting viruses in RTS Co-infecting viruses in stool Co-infecting viruses in further samples
KIPyV (adult patients) 1 Double Cord-Blood- Transplantation Chronic (skin, gut - max. IV°) Cidofovir (days +121 to +272) HHV6, HSV HHV6 HHV6 (leukocytes), BKV, HHV6 (urine)
  2 Allogeneic PBSCT Chronic ( skin, gut - max. IV°) Cidofovir, Ribavirin ( days +118 to +176) EBV, HHV6, HSV Adenovirus, EBV EBV, HHV6, Adenovirus (leukocytes)
  3 Allogeneic BMT Acute (skin - max. II°) Foscarnet ( days +19 to +55), Cidofovir ( days +55 to +138) HHV6, EBV none EBV (leukocytes)
  4 Allogeneic PBSCT Acute (gut - max. III°) none HHV6 HHV6 HHV6, EBV (leukocytes)
WUPyV (infant) 5 Allogeneic PBSCT Chronic (pre-PBSCT: skin, gut, hematopoietic system - max. III°) Cidofovir ( days +17 to +58) HHV6, Adenovirus, HHV7, HSV Norovirus, Adenovirus, HHV6 HHV6 (urine)
  1. Clinical data summary for the HSCT patients that tested positive for WUPyV and KIPyV including detected co-infecting viruses throughout the observation period and antiviral therapy; Antiviral therapy: all patients received prophylactic Acyclovir therapy. Further antiviral therapy is depicted with time-points (day 0: day of HSCT). Co-infecting viruses in RTS, stool and further samples in order of detection frequency. GvHD: Graft versus Host Disease; RTS: respiratory tract samples, PBSCT: peripheral blood stem cell transplantation.